🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: AI plus ribociclib

Found 17 matching trials

Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer

PHASE2

Aromatase inhibitor (AI) + CDK4/6 inhibitor is settled down as the standard...

Status

Recruiting

Location

Korea university Guro hospital

Start Date

2023-05-31

Trial ID

NCT05816655

Treatments Being Tested

Fulvestrant plus AI plus ribociclib AI plus ribociclib

Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia

N/A

This prospective, observational, multicenter study aims at evaluating the e...

Status

Recruiting

Location

Novartis Investigative Site

Start Date

2025-12-03

Trial ID

NCT06930859

Treatments Being Tested

Ribociclib Letrozole Anastrozole

Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer

PHASE1

The primary objective of Phase 1b will be to evaluate the safety and tolera...

Status

Terminated

Location

Holy Cross Health Fort Lauderdale - Holy Cross Hospital

Start Date

2023-01-09

Trial ID

NCT05384119

Treatments Being Tested

TTI-101 Palbociclib Aromatase inhibitor (AI)fulvestrant ribociclib

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

PHASE3

The purpose of this study is to generate evidence on an alternative dosing ...

Status

Recruiting

Location

Ironwood Cancer & Research Centers

Start Date

2024-10-29

Trial ID

NCT06377852

Treatments Being Tested

Palbociclib 125mg Ribociclib 600mg Ribociclib Palbociclib

A Non-interventional Study for Kisqali (Ribociclib) in Combination With an Aromatase Inhibitor for Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer at High Risk of Recurrence

N/A

This non-interventional observational study evaluates the real-world effect...

Status

Recruiting

Location

Novartis Investigative Site

Start Date

2025-02-20

Trial ID

NCT06830720

Treatments Being Tested

ribociclib + AI ± LHRH abemaciclib + ET ± LHRH ET mono ± LHRH

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

PHASE3

The goal of this clinical trial is to assess the efficacy, safety and toler...

Status

Recruiting

Location

Mayo Clinic - Scottsdale

Start Date

2023-10-31

Trial ID

NCT05696626

Treatments Being Tested

Lasofoxifene in combination with abemaciclib Fulvestrant in combination with abemaciclib

A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer

N/A

Palbociclib, the first oral CDK4/6 inhibitor, is an approved medicine indic...

Status

Active Not Recruiting

Location

Pfizer New York

Start Date

2024-06-24

Trial ID

NCT06495164

Treatments Being Tested

Palbociclib Aromatase inhibitor Ribociclib Abemaciclib

Ribociclib in Combination With Adjuvant Endocrine Therapy for Patients With Early High-risk HR+HER2- Breast Cancer

N/A

The goal of this observational study is to learn about the effects of using...

Status

Recruiting

Location

Second Affiliated Hospital of Zhejiang University School of Medicine

Start Date

2024-01-01

Trial ID

NCT06587789

Treatments Being Tested

Ribociclib

A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line Treatment

N/A

This is a non-interventional observational study conducted in Germany to ev...

Status

Completed

Location

Novartis Investigative Site

Start Date

2017-10-09

Trial ID

NCT06311383

Treatments Being Tested

First-line Ribociclib + endocrine therapy First-line endocrine therapy First-line chemtherapy

Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel)

PHASE2

To compare the efficacy and safety of ribociclib in combination with aromat...

Status

Recruiting

Location

Jiangsu Provincial People's Hospital

Start Date

2024-08-13

Trial ID

NCT06656624

Treatments Being Tested

Ribociclib combined with AI±OFS physician's choice of chemotherapy sequential Ribociclib combined with AI±OFS

Previous Next